ShareValue scores for WWB: Valuation 42, Quality 50, Growth 50, Health 39.

WWB
NASDAQ

Windward Bio Group AG Common Shares

$24.01(+6.05%)

Updated

Loading chart...
Sentiment

Pulse

Rating

Moderate

Trap Risk

P/E to median

Not enough data
Valuation
42
Fair Value

vs US-listed Healthcare stocks without a market-cap tier

Price vs Value
Quality
50
Moderate
Business Strength
Growth
50
Moderate
Revenue & Earnings
Health
39
Stressed
Financial Stability
Price trend
N/A
N/a
Separate from the four scores

Company Details

About

Windward Bio Group AG operates as a clinical stage biotechnology company that develops ultra-long-acting antibody medicines for patients with respiratory and dermatologic diseases. Its drug candidates WIN378, an ultra-long-acting and novel fully human monoclonal antibody, which has completed Phase I clinical study that inhibits thymic stromal lymphopoietin (TSLP); and WIN027, an ultra-long-acting bispecific antibody that is in Phase I clinical study simultaneously targets TSLP and interleukin-13 (IL-13) and two clinically validated drivers of inflammatory disease. The company has collaboration agreements with Sichuan Kelun-Biotech BioPharmaceutical Co., Ltd, Harbour BioMed (Shanghai) Co., Ltd, and Qyuns Therapeutics Co., Ltd. Windward Bio Group AG was incorporated in 2024 and is based in Basel, Switzerland.

Score Analysis

AI Investment Thesis

Powered by DeepSeek. For research only. Not financial advice.

Sources:[1][2][3][4][5]

Windward Bio Group AG Common Shares is fairly valued: its P/B of 6.20 is higher than 79% of US-listed healthcare peers, while P/E, EV/EBITDA and PEG are not available.

Data as of:Nov 20, 2026

By using ShareValue.ai you agree to our Terms and Privacy Policy. Educational platform, not investment advice.